



# Does sentinel node mapping impact morbidity and quality of life in endometrial cancer?

Bruna Tirapelli Goncalves <sup>1</sup>, Ricardo Dos Reis <sup>2</sup>, Reitan Ribeiro <sup>3</sup>, Renato Moretti-Marques <sup>4</sup>, Fernanda Karoline Schamme <sup>3</sup>, Gabriela Silva Oliveira <sup>2</sup>, Audrey Tieko Tsunoda <sup>3,5,6</sup>, Vanessa Alvarenga-Bezerra <sup>4</sup>, Andre Lopes <sup>7</sup>, Caroline Batista Pinheiro Pastore <sup>7</sup>, Lillian Yuri Kumagai <sup>1</sup>, Carlos Chaves Faloppa <sup>1</sup>, Henrique Mantoan <sup>1</sup>, Levon Badiglian-Filho <sup>1</sup>, Louise De Brot <sup>8</sup>, Carlos Eduardo Mattos Cunha Andrade <sup>2</sup>, Glauco Baiocchi <sup>1</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/ijgc-2023-004555>).

For numbered affiliations see end of article.

## Correspondence to

Dr Glauco Baiocchi, Department of Gynecologic Oncology, AC Camargo Cancer Center, Sao Paulo, São Paulo, Brazil; glauco.baiocchi@accamargo.org.br

Received 11 April 2023

Accepted 12 July 2023

Published Online First

12 September 2023



© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Goncalves BT, Dos Reis R, Ribeiro R, et al. *Int J Gynecol Cancer* 2023;**33**:1548–1556.

## ABSTRACT

**Objectives** To evaluate the prevalence of post-operative complications and quality of life (QoL) related to sentinel lymph node (SLN) biopsy vs systematic lymphadenectomy in endometrial cancer.

**Methods** A prospective cohort included women with early-stage endometrial carcinoma who underwent lymph node staging, grouped as follows: SLN group (sentinel lymph node only) and SLN+LND group (sentinel lymph node biopsy with addition of systematic lymphadenectomy). The patients had at least 12 months of follow-up, and QoL was assessed by European Organization for Research and Treatment of Cervical Cancer Quality of Life Questionnaire 30 (EORTC-QLQ-C30) and EORTC-QLQ-Cx24. Lymphedema was also assessed by clinical evaluation and perimetry.

**Results** 152 patients were included: 113 (74.3%) in the SLN group and 39 (25.7%) in the SLN+LND group. Intra-operative surgical complications occurred in 2 (1.3%) cases, and all belonged to SLN+LND group. Patients undergoing SLN+LND had higher overall complication rates than those undergoing SLN alone (33.3% vs 14.2%;  $p=0.011$ ), even after adjusting for confound factors (OR=3.45, 95% CI 1.40 to 8.47;  $p=0.007$ ). The SLN+LND group had longer surgical time ( $p=0.001$ ) and need for admission to the intensive care unit ( $p=0.001$ ). Moreover, the incidence of lymphocele was found in eight cases in the SLN+LND group (0 vs 20.5%;  $p<0.001$ ). There were no differences in lymphedema rate after clinical evaluation and perimetry. However, the lymphedema score was highest when lymphedema was reported by clinical examination at 6 months (30.1 vs 7.8;  $p<0.001$ ) and at 12 months (36.3 vs 6.0;  $p<0.001$ ). Regarding the overall assessment of QoL, there was no difference between groups at 12 months of follow-up.

**Conclusions** There was a higher overall rate of complications for the group undergoing systematic lymphadenectomy, as well as higher rates of lymphocele and lymphedema according to the symptom score. No difference was found in overall QoL between SLN and SLN+LND groups.

## INTRODUCTION

Endometrial cancer is the most common malignancy of the female genital tract in developed countries,<sup>1</sup> and lymph node dissection has been considered as part of endometrial cancer staging since the seminal

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Despite the growing evidence of SLN mapping in endometrial cancer, prospective studies addressing morbidity and impact on QoL are lacking.

## WHAT THIS STUDY ADDS

⇒ We prospectively addressed morbidity and QoL in patients that underwent SLN compared to SLN with backup lymphadenectomy.  
⇒ We found that the addition of lymphadenectomy to SLN biopsy significantly increased the early complication rates and lymphedema according to the symptom score.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ While the results of prospective trials on SLN biopsy are still awaited, the present study supports SLN biopsy as a staging method with lower surgical complication rates.

Gynecologic Oncology Group GOG-33 study, though never being the study's aim.<sup>2</sup>

Conversely, sentinel lymph node (SLN) biopsy has emerged as an acceptable and accurate surgical strategy for endometrial cancer staging even for high-grade histologies.<sup>3,4</sup> SLN assessment potentially prevents the early morbidity associated with a systematic lymphadenectomy, such as neurovascular injury and lymphocyst formation.<sup>5</sup> Moreover, late morbidity, such as lower limb lymphedema, can also be avoided, leading to a better treatment experience and quality of life.<sup>6,7</sup>

Only recent data support a high prevalence of lower limb lymphedema after uterine cancer treatment. In early-stage cervical cancer, the SENTIREC study reported a prevalence of lower limb lymphedema in 5.6% for women who underwent the SLN mapping compared with 32.2% after the addition of pelvic lymphadenectomy.<sup>8</sup> Moreover, a large retrospective endometrial cancer series evaluated patients undergoing SLN and noted a lower rate of patient-reported

lymphedema than with lymphadenectomy (27% vs 41%,  $p=0.002$ ).<sup>9</sup>

Cancer treatment has a major negative impact on a woman's life. In this scenario, the high level of psychological stress has profound negative repercussion on the quality of life (QoL), mainly in the first year of treatment, for patients, partners, and family members.<sup>10</sup> Therefore, improvement of surgical morbidity knowledge in gynecological cancer surgery and how complications are valued by patients, and its impact on global health might help health providers to deliver tailored support and treatment.<sup>11</sup>

Despite the growing evidence of SLN mapping in endometrial cancer, prospective studies addressing morbidity and impact on QoL are still lacking.<sup>12</sup> In this prospective study, which includes data from an interim analysis of an ongoing trial (NCT03366051), we hypothesized that the addition of lymphadenectomy to SLN mapping in endometrial cancer is related to higher morbidity and has a negative impact on QoL in comparison with SLN biopsy alone.

## METHODS

The complications and lymphedema assessment, surveillance methods and statistical analysis are detailed in online supplemental file 1.

### Patients

Between December 2017 and April 2022, patients with presumed early-stage endometrial cancer who underwent SLN mapping were prospectively recruited. We included patients with high-risk tumors from the ALICE trial (NCT03366051)—a multicentric open-label prospective randomized ongoing trial. The trial is assigning high-risk patients to undergo SLN mapping only or SLN mapping with systematic lymphadenectomy.<sup>13</sup>

Briefly, the ALICE trial is including patients with high-risk tumors, such as high-grade histology (endometrioid grade 3, serous, clear cell, and carcinosarcoma), endometrioid grades 1 or 2 with myometrial invasion of  $\geq 50\%$  or cervical invasion, clinically suitable to undergo systematic lymphadenectomy. For the present study we also included patients not suitable for ALICE trial and with low-risk tumors that only had SLN mapping.

Finally, patients were divided in two groups: SLN group (only SLN mapping) and SLN+LND group (SLN mapping with addition of lymphadenectomy). The study was approved by the institutions' review boards (#2441-17B) and all patients signed an informed consent. The data were collected, input, and managed using Research Electronic Data Capture software.<sup>14</sup>

### Patient-reported Outcome

The first data were captured before surgery and during follow-up at 1, 6, and 12 months with the application of QoL questionnaires by the European Organization for Research and Treatment of Cervical Cancer Quality of Life Questionnaire 30 (EORTC-QLQ-C30) and EORTC-QLQ-Cx24. All the scales and

single-item measure scores range from 0 to 100. The QoL scores were analyzed according to EORTC Scoring Manual.<sup>15</sup>

## RESULTS

### Patients' Demographics

The study's flowchart is depicted in Figure 1. Clinical and pathological data are summarized in Table 1.

The study included 152 patients, allocated in two groups: SLN group ( $n=113$ ; 74.3%) and SLN+LND group ( $n=39$ ; 25.7%). Indocyanine green was used in 84 (55.3%) cases and blue dye in 68 (44.7%). Only 14 (9.2%) cases had a unilateral detection, mostly in blue dye cases ( $n=10$ ;  $p=0.035$ ).

The median number of resected SLN (entire cohort) was 2,<sup>1-7</sup> and 18 (11.8%) cases had lymph node metastasis—6 (3.9%) macrometastasis, 10 (6.6%) micrometastasis, and 2 (1.3%) isolated tumor cells. Additionally, the median resected lymph nodes in the group SLN+LND was 22 (range 4–45), with median pelvic and para-aortic lymph nodes of 16 (range 4–31) and 10 (range 2–22), respectively.

There were no differences between the groups in age ( $p=0.15$ ), BMI ( $p=0.62$ ) and minimally invasive approach ( $p=0.82$ ). However, the SLN+LND group had longer surgical time (mean,  $274\pm 65$  vs  $160\pm 104$  min;  $p<0.001$ ) and intensive care unit use (23.1% vs 3.5%;  $p<0.001$ ). Notably, 20 (13.1%) cases were considered American Society of Anesthesiologists (ASA) 3 patients, with higher rates in the SLN+LND group (25.6%) than in the SLN group (8.8%). (Table 1)


As anticipated, the groups differed with regard to pathologic features. Patients in the SLN+LND group were more likely to have non-endometrioid histologies (30.8% vs 11.5%;  $p=0.005$ ), grade 3 tumors (81.6% vs 21.2%;  $p<0.001$ ), deep myometrial invasion (41% vs 14.2%;  $p<0.001$ ), and presence of lymphovascular space invasion (38.5% vs 20.4%;  $p=0.02$ ). Therefore, the SLN+LND group received more adjuvant treatment (87.2% vs 39.8%;  $p<0.001$ ). (Table 1)

### Intra-Operative and Early Complications ( $\leq 30$ days)

Two (5.1%) patients had an intra-operative complication with obturator nerve injury (one thermal injury and one partial sectioning), and both belonged to the SLN+LND group ( $p=0.065$ ). Early complications occurred in 29 (19.1%) cases. Patients who underwent SLN+LND had overall higher surgical complication rates than those who underwent only SLN (33.3% vs 14.2%; OR=3.03, 95% CI 1.29 to 7.09;  $p=0.009$ ). Patients in the SLN group had grades 1, 2, and 3 complications in 10.6%, 2.6%, and 0.8%, respectively. Moreover, for SLN+LND group, complications grade 1, 2, 3 and 5 occurred in 17.9%, 10.2%, and 2.5% and 2.5%, respectively. Notably, grade  $\geq 3$  complications were uncommon in both groups (0.8% vs 5%;  $p=0.16$ ).

Four patients had two or more types of complications: 1 (0.8%) in the SLN group and 3 (7.7%) patients in the SLN+LND group. The surgical complications are depicted in Table 2.

We also evaluated the impact of age, ASA, body mass index (BMI) and minimally invasive approach on the risk of post-operative complications. ASA 3 did not impact the risk of complication (OR=1.15, 95% CI 0.35 to 3.77;  $p=0.1$ ), similarly for age (OR=0.98, 95% CI 0.93 to 1.03;  $p=0.50$ ), BMI (OR=1.00, 95% CI 0.94 to 1.07;  $p=0.81$ ), and minimally invasive approach (OR=0.33, 95% CI 0.10



**Figure 1** Study flowchart. SLN: Sentinel Lymph Node; LND: Lymphadenectomy; QoL: Quality of life. <sup>a</sup>Endometrioid G1/2 and myometrial invasion <50%. <sup>b</sup>Endometrioid G3, non-endometrioid and myometrial invasion ≥50%. \*Patients from Alice Trial (NCT 03366051).

to 1.11;  $p=0.073$ ). Moreover, the addition of lymphadenectomy (SLN+LND group) maintained as independent variable for the risk of complication after adjusting for surgical approach and ASA (OR=3.45, 95% CI 1.40 to 8.47;  $p=0.007$ ).

Eight patients (5.3%) developed lymphocele with median post-operative time of 142 days (range 24–401). Notably, lymphocele occurred only in patients who underwent lymphadenectomy ( $p<0.001$ ) and 3 (37.5%) cases were symptomatic—1 (12.5%) case underwent image guided drainage and 2 (25%) received intravenous antibiotics.

### Lymphedema

Lymphedema was noted after clinical evaluation in 33 (24.4%) patients—84.8% ( $n=28$ ) grade 1 and 15.2% ( $n=5$ ) grade 2. Lymphedema after clinical examination was found in 21.2% of patients in the SLN group and 33.3% in the SLN+LND group

at 12 months after surgery ( $p=0.14$ ). We noted clinical grade 1 lymphedema for SLN and SLN+LND groups in 15.9% ( $n=18$ ) and 25.6% ( $n=10$ ) of cases, respectively. Moreover, grade 2 lymphedema for SLN and SLN+LND groups were 2.6% ( $n=3$ ) and 5.1% ( $n=2$ ), respectively. We did not record grade 3 lymphedema.

Notably, the increase difference volumes of  $\geq 10\%$  from 6 to 12 months did not differ between groups, being 23.2% ( $n=19/82$ ) for SLN and 13.3% ( $n=4/30$ ) for SLN+LND groups ( $p=0.38$ ). Conversely, we found an association between clinical and lymphedema assessment reported by QoL questionnaire ( $p<0.001$ ). The lymphedema score had the highest mean when lymphedema was reported by clinical examination at 6 months (30.1 vs 7.8;  $p<0.001$ ) and at 12 months (36.3 vs 6.0;  $p<0.001$ ). We found no association between

**Table 1** Clinical and pathological characteristics of women undergoing primary surgery for endometrial cancer.

Characteristics	SLN (n=113)	SLN+LND (n=39)	Total (n=152)	P value
	Mean (SD)	Mean (SD)	Mean (SD)	
Age	60.3 (8.0)	62.4 (6.0)	60.8 (7.5)	0.15
BMI	30.1 (6.5)	30.7 (5.9)	30.3 (6.4)	0.62
Surgical time length (min)	160 (65)	274 (104)	189 (91.5)	<0.001
	n (%)	n (%)		P value
ASA				<0.001
ASA 1	5 (4.4%)	8 (20.5%)	13 (8.5%)	
ASA 2	98 (86.7%)	21 (53.8%)	119 (78.3%)	
ASA 3	10 (8.8%)	10 (25.6%)	20 (13.2%)	
ICU				<0.001
No	109 (96.5%)	30 (76.9%)	139 (91.4%)	
Yes	4 (3.5%)	9 (23.1%)	13 (8.6%)	
ECOG*				0.68
0	90 (81.8%)	28 (75.7%)	118 (80.3%)	
1	17 (15.5%)	8 (21.6%)	25 (17.0%)	
2	3 (2.7%)	1 (2.7%)	4 (2.7%)	
Randomization				<0.001
No	80 (70.8%)	3 (7.7%)	83 (54.6%)	
Yes	33 (29.2%)	36 (92.3%)	69 (45.4%)	
Surgical approach				1.0
Laparotomy	10 (8.8%)	3 (7.7%)	13 (8.6%)	
MIS	103 (91.2%)	36 (92.3%)	139 (91.4%)	
Histological grade†				<0.001
1	57 (50.4%)	3 (7.9%)	60 (39.7%)	
2	32 (28.3%)	4 (10.5%)	36 (23.8%)	
3	24 (21.2%)	31 (81.6%)	55 (36.4%)	
Histological type				0.11
Endometrioid	100 (88.5%)	27 (69.2%)	127 (83.6%)	
Serous	4 (3.5%)	4 (10.3%)	8 (5.3%)	
Clear cell	1 (0.9%)	1 (2.6%)	2 (1.3%)	
Mixed	2 (1.8%)	2 (5.1%)	4 (2.6%)	
Carcinosarcoma	2 (1.8%)	3 (7.7%)	5 (3.3%)	
Dedifferentiated	4 (3.5%)	2 (5.1%)	6 (3.9%)	
Histological type				0.005
Endometrioid	100 (88.5%)	27 (69.2%)	127 (83.6%)	
Non-endometrioid	13 (11.5%)	12 (30.8%)	25 (16.4%)	
LVSI				0.02
Absent	90 (79.6%)	24 (61.5%)	114 (75%)	
Present	23 (20.4%)	15 (38.5%)	38 (25%)	
Cervical stromal invasion				0.18
No	106 (93.8%)	34 (87.2%)	140 (92.1%)	
Yes	7 (6.2%)	5 (12.8%)	12 (7.9%)	
Myometrial invasion				<0.001
No invasion	20 (17.7%)	9 (23.1%)	29 (19.1%)	
<50%	77 (68.1%)	14 (35.9%)	91 (59.9%)	
≥50%	16 (14.2%)	16 (41%)	32 (21.1%)	

Continued

## Original research

**Table 1** Continued

Characteristics	SLN (n=113)	SLN+LND (n=39)	Total (n=152)	P value
	Mean (SD)	Mean (SD)	Mean (SD)	
SLN metastasis	13 (11.5%)	5 (10.2%)	18 (11.8%)	0.92
ITC	2 (15.3%)	0	2 (11.1%)	
Micrometastasis	7 (53.8%)	3 (60%)	10 (55.5%)	
Macrometastasis	4 (30.7%)	2 (40%)	6 (33.4%)	
Adjuvant therapy				
No	68 (60.2%)	5 (12.8%)	73 (48%)	<0.001
Yes	45 (39.8%)	34 (87.2%)	79 (52%)	
Type of adjuvant therapy				
Chemotherapy only	1 (2.2%)	1 (2.9%)	2 (2.5%)	0.60
EBRT only	3 (6.7%)	2 (5.9%)	5 (6.3%)	
Chemotherapy+EBRT	4 (8.9%)	3 (8.8%)	7 (8.9%)	
VB only	12 (26.7%)	10 (29.4%)	22 (27.8%)	
EBRT+VB	9 (20%)	2 (5.9%)	11 (13.9%)	
Chemotherapy+VB	0 (0%)	1 (2.9%)	1 (1.3%)	
Chemotherapy+EBRT+VB	16 (35.6%)	15 (44.1%)	31 (39.2%)	

\*Missing data in 5 cases (3 cases SLN and 2 SLN+LND).  
†Missing data in 1 case (SLN+LND).  
ASA, American Society of Anesthesiologists; BMI, body mass index; EBRT, external beam radiotherapy; ECOG, Eastern Cooperative Oncology Group; ICU, intensive care unit; ITC, isolated tumor cells; LND, lymphadenectomy; LVSI, lymphovascular space invasion; MIS, minimally invasive surgery; SLN, sentinel lymph node biopsy; VB, vaginal brachytherapy.

adjuvant external beam radiotherapy and lymphedema ( $p=0.73$ ).

**Patient-Reported Outcome**

The full function and symptoms scores from the study groups are depicted in online supplemental tables 1,2.

**Function Scores**


Although the graphics seem to show better global health status scores in favor of the SLN group during the follow-up, we could not find a statistically difference between groups. The social functioning score was most preserved at 1 month (means 83.4 vs 71.7;  $p=0.012$ ) and 6 months (means 86.8

**Table 2** Description of early surgical complications after sentinel node biopsy±lymphadenectomy.

Early surgical complications	SLN, n (%)	SLN+LND, n (%)	Total
Urinary tract infection	5 (17.2%)	0	5 (17.2%)
Surgical wound infection	4 (13.8%)	1 (3.4%)	5 (17.2%)
Seroma	2 (6.9%)	0	2 (6.9%)
Vaginal bleeding	3 (10.3%)	0	3 (10.3%)
Fecaloma	0	4 (13.8%)	4 (13.8%)
Sepsis	0	1 (3.4%)	1 (3.4%)
Abdominal wall hematoma	0	1 (3.4%)	1 (3.4%)
Neuropathic pain	0	2 (6.9%)	2 (6.9%)
Skin dehiscence	0	1 (3.4%)	1 (3.4%)
Lymphocele	0	2 (6.9%)	2 (6.9%)
Intense acute pain	1 (3.4%)	0	1 (3.4%)
Vascular complications	0	1 (3.4%)	1 (3.4%)
Drug allergy	1 (3.4%)	0	1 (3.4%)
Total	16 (55.2%)	13 (44.8%)	29 (100%)

SLN, sentinel lymph node biopsy; LND, lymphadenectomy.





**Figure 2** Graphical representation of mean functions scores during follow-up comparing SLN and SLN+LND groups: (A) global health status; (B) role functioning; (C) social functioning; (D) physical function.

vs 74.01;  $p=0.011$ ) after surgery for the SLN group than for the SLN+LND group. Moreover, physical function scores were most preserved in the SLN group during follow-up and at 1 month (means, 78.3 vs 71.7;  $p=0.03$ ) (Figure 2).

#### Symptom Scores

Patients in the SLN+LND group experienced greater symptoms related to lymphedema compared with SLN group at 12 months of follow-up (means 23.5 vs 12.4;  $p=0.022$ ). Additionally, a better symptom experience score was recorded at 6 months and related to general symptoms for the SLN group compared with that for the SLN+LND group (means, 5.61 vs 9.38;  $p=0.047$ ), however with no difference at 12 months (5.8 vs 8.3;  $p=0.17$ ). (Figure 3)

## DISCUSSION

### Summary of Main Results

We performed an interim analysis for complication rates and QoL including patients from the ongoing ALICE trial and cases not suitable for the trial with addition of low-risk tumors, although with similar follow-up. We found that patients who underwent additional lymphadenectomy had increased early surgical morbidity and some decreased QoL scores recorded in function and symptoms questionnaires. Moreover, this is the first study that prospectively evaluated lymphedema and QoL comparing SLN mapping and SLN with addition of lymphadenectomy in endometrial cancer, and we noted a higher rate of lymphedema after lymphadenectomy.


### Results in the Context of Published Literature

#### Early Complications

While the landscape of lymph node staging in endometrial cancer is shifting from systematic lymphadenectomy to SLN biopsy,<sup>16</sup> data comparing a complications' profile of the two methods are lacking. Dioun et al<sup>17</sup> retrospectively analyzed a large database ( $n=45\,381$ ), and SLN mapping was associated with a decreased risk of complications compared with lymphadenectomy (5.9% vs 7.3%;  $RR=0.85$ , 95% CI 0.77 to 0.95) after adjusting for confounders. Accorsi et al<sup>6</sup> recorded higher intra-operative ( $RR=14.25$ , 95% CI 1.85 to 19.63) and 30-day complication rates ( $RR=3.11$ , 95% CI 1.62 to 5.98) for women who underwent lymphadenectomy compared with SLN mapping. Conversely, Casarin et al<sup>18</sup> noted that SLN biopsy ( $n=188$ ) had a shorter mean operative time, less blood loss compared with lymphadenectomy ( $n=198$ ), but with no difference in complication rates. Notably, the three studies found that SLN mapping did not worsen morbidity compared with no lymph node staging.

In our study, patients who received additional systematic lymphadenectomy had overall more early complications compared with SLN mapping group. As the two groups were not similar in all clinical variables, we also performed an adjustment for possible confounding factors, and the addition of lymphadenectomy remained an independent risk for complications. Notably, most complications were low grade (grades 1 and 2), and therefore better captured in a prospective design.

For QoL, HORIZONS UK was a large ( $n=1222$ ), single-arm study that included all gynecologic cancers and evaluated predictive



**Figure 3** Graphical representation of mean symptom scores during follow-up comparing SLN and SLN+LND groups: (A) lymphoedema; (B) symptom experience. LND, lymphadenectomy; SLN sentinel lymph node.

factors that affected a women's life at diagnosis and up to 12 months. The authors noted that QoL declined from baseline to 3 months, followed by an improvement at 12 months.<sup>11</sup> Our study aimed to compare two methods of node staging; we found some specific worse scores' outcomes for the SLN+LND group, reflecting the potential morbidity associated with lymphadenectomy. However, we found no statistically significant difference between groups for global health status score.

#### Lymphoedema Assessment

We assessed the development of lymphoedema by three different methods during 12 months of follow-up. The GOG 244 study suggested at least 2 years follow-up for lower limb lymphoedema symptoms,<sup>19</sup> similar to a recent prospective study in cervical cancer that suggested lymphoedema diagnosis after 15 months of surgery.<sup>20</sup> Additionally, Leitao et al published a large retrospective

study that incorporated a patient-reported outcomes questionnaire in lymphoedema and noted an increased lymphoedema rate for patients after lymphadenectomy compared with only SLN (40.9% vs 27.2%;  $p=0.002$ ).<sup>9</sup> The authors reported a long median follow-up time of 63.2 and 93.1 months for SLN and lymphadenectomy groups, respectively.

We found a clinical lymphoedema rate of 33.3% in the SLN+LND group compared with 21.2% in the SLN group, which was not statistically significant and higher than expected for the SLN group compared with results from other studies. In the study by Geppert et al, lymphoedema was reported for the SLN and lymphadenectomy groups in only 1.3% and 18.1% of cases, respectively.<sup>21</sup> Lower limb edema in women with endometrial cancer might have a multifactorial origin, such as weight gain, sedentarism, and hormonal changes, and we might argue whether other factors would lead to

lower-limb changes rather than the resection of pelvic SLNs. Moreover, most lymphedema were classified as grade 1.

Like the GOG 244 study,<sup>19</sup> we found no correlation between the clinical criteria and perimetry. A possible explanation is that the lower limb extremity (foot) swelling is not captured by perimetry during leg circumference measurement, and this leads to discordance between perimetry and clinical evaluation or reported symptoms. Nevertheless, methods for lymphedema diagnosis are still controversial,<sup>20</sup> and the evaluation of lower limbs only by volume may neglect the dynamic process of lower limb lymphedema development. Growing evidence supports patient-reported outcomes in surgical oncology research and it is currently accepted<sup>22–23</sup> for the morbidity symptom assessment.<sup>24</sup> Moreover, the correlation between patient-reported outcomes and clinical evaluation has been considered a standard practice with good reproducibility.<sup>19</sup> Yet, we noted a worse mean QoL score regarding lymphedema for SLN+LND at 12 months of follow-up compared with only SLN and a relation between the EORTC score for lymphedema and clinical evaluation.

Two other predictive factors for lymphedema should be considered. First, pelvic radiation has been suggested as an important risk factor for lymphedema.<sup>9–25</sup> However, we did not find a relation between post-operative pelvic radiation and lymphedema, which might be explained by our short follow-up time. Second, we should report that all patients in the SLN+LND group had the circumflex lymph nodes spared, a surgical approach that might prevent lower limb lymphedema in patients who undergo full pelvic lymphadenectomy.<sup>26</sup>

### Strengths and weaknesses

The present series is the first that prospectively addressed morbidity and QoL for women who underwent SLN compared with SLN with back-up lymphadenectomy. Moreover, lymphedema was assessed by three methods and although including patients during the pandemic, we had a low evaluation loss. However, it should be noted that inherent and unadjusted confounding factors might always affect the results as not all patients were part of the ongoing randomized study, leading to heterogeneous groups for some clinical and uterine features.

### Implications for practice and future research

The present study supports SLN biopsy as a staging method with lower surgical complication rate. Moreover, the early recognition of lower-limb lymphedema during the first 12 months of follow-up may be appropriate by clinical and patient-reported outcome rather than perimetry. Interestingly, we had a high rate of lymphedema even after SLN biopsy compared with previous reports and it may be explained by the complexity of lymphedema recognition and classification, as well as its multifactorial origin.

### CONCLUSIONS

We found that the addition of lymphadenectomy to SLN biopsy significantly increased the early complication rates as well as leading to higher rates of lymphocele and lymphedema according to the symptom score. Better QoL scores were recorded for the SLN group in some specific function and symptoms questionnaires;

however, no difference was found for overall QoL when SLN biopsy was compared with back-up lymphadenectomy.

### Author affiliations

<sup>1</sup>Department of Gynecologic Oncology, AC Camargo Cancer Center, Sao Paulo, Brazil

<sup>2</sup>Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos, Brazil

<sup>3</sup>Department of Gynecologic Oncology, Erasto Gaertner Hospital, Curitiba, Brazil

<sup>4</sup>Department of Gynecologic Oncology, Albert Einstein Hospital, Sao Paulo, Brazil

<sup>5</sup>HCor Oncology, Sao Paulo, Brazil

<sup>6</sup>PPGTS/Pontificia Universidade Catolica do Parana, Curitiba, Brazil

<sup>7</sup>Department of Gynecologic Oncology, Sao Camilo Oncologia, Sao Paulo, Brazil

<sup>8</sup>Department of Anatomic Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil

**Twitter** Andre Lopes @andrelopesMD, Levon Badiglian-Filho @Levon66175314 and Glauco Baiocchi @glauco baiocchi

**Contributors** Study concept and design: RDR, BG, GB; data acquisition: CP, VA, GO, FS, RM-M, RDR, RR, LDB, BG, LYK, CCF, GB; quality control of data: CeEMdCA, ATT, RDR, RR, BTG, HM, CCF, GB; data analysis and interpretation: AL, RDR, BG, LYK, LB-F, LDB, GB; statistical analysis: BG, GB; manuscript preparation and editing: BG, GB; manuscript review: all authors; guarantor of the manuscript: GB.

**Funding** This study was partially sponsored by Brazilian National Research Council (CNPq) #307703/2019-3.

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Ethics approval** This study involves human participants and was approved by Comite de Etica em Pesquisa da Fundação Antonio Prudente #2441-17B. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. The data and material will be available by the authors upon reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

### ORCID iDs

Bruna Tirapelli Goncalves <http://orcid.org/0000-0002-1620-7570>

Ricardo Dos Reis <http://orcid.org/0000-0002-8271-3690>

Reitan Ribeiro <http://orcid.org/0000-0002-4323-3854>

Andre Lopes <http://orcid.org/0000-0002-4986-8738>

Levon Badiglian-Filho <http://orcid.org/0000-0001-8741-166X>

Louise De Brot <http://orcid.org/0000-0002-0551-4401>

Glauco Baiocchi <http://orcid.org/0000-0002-8193-5582>

### REFERENCES

- 1 Siegel RL, Miller KD, Fuchs HE, *et al.* Cancer statistics, 2021. *CA Cancer J Clin* 2021;71:7–33.
- 2 Creasman WT, Morrow CP, Bundy BN, *et al.* Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. *Cancer* 1987;60(8 Suppl):2035–41.
- 3 Marchocki Z, Cusimano MC, Clarfield L, *et al.* Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. *Am J Obstet Gynecol* 2021;225:367.
- 4 Baiocchi G, Mantoan H, Kumagai LY, *et al.* The impact of sentinel node-mapping in staging high-risk endometrial cancer. *Ann Surg Oncol* 2017;24:3981–7.
- 5 Diniz TP, Drizlionoks E, Faloppa CC, *et al.* Impact of sentinel node mapping in decreasing the risk of Lymphocele in endometrial cancer. *Ann Surg Oncol* 2021;28:3293–9.
- 6 Accorsi GS, Paiva LL, Schmidt R, *et al.* Sentinel lymph node mapping vs systematic lymphadenectomy for endometrial cancer:



- surgical morbidity and lymphatic complications. *J Minim Invasive Gynecol* 2020;27:938–45.
- 7 Rossi EC, Kowalski LD, Scalici J, *et al.* A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. *Lancet Oncol* 2017;18:384–92.
  - 8 Sponholtz SE, Ezendam NPM, de Rooij BH, *et al.* SENTIREC - the sentinel node mapping in women with cervical cancer study - patient-reported early lymphedema and its impact on quality of life. *Gynecol Oncol* 2022;164:463–72.
  - 9 Leitao MM, Zhou QC, Gomez-Hidalgo NR, *et al.* Patient-reported outcomes after surgery for endometrial carcinoma: prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. *Gynecol Oncol* 2020;156:147–53.
  - 10 Yeh Y-C, Sun J-L, Lu C-H. Associations between perceived stress and quality of life in gynaecologic cancer patient-family caregiver dyads. *Eur J Oncol Nurs* 2021;55:102060.
  - 11 Glasspool R, Wheelwright S, Bolton V, *et al.* Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: results from the HORIZONS UK national cohort study. *Gynecol Oncol* 2022;165:610–8.
  - 12 Russo S, Walker JL, Carlson JW, *et al.* Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers. *Gynecol Oncol* 2021;160:625–32.
  - 13 Baiocchi G, Andrade CEMC, Ribeiro R, *et al.* Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial). *Int J Gynecol Cancer* 2022;32:676–9.
  - 14 Harris PA, Taylor R, Minor BL, *et al.* The REDCap consortium: building an international community of software platform partners. *J Biomed Inform* 2019;95:103208.
  - 15 Scott NW, Fayers PM, Aronson NK, *et al.* EORTC QLQ-C30 Reference values; 2008Jul.
  - 16 Matsuo K, Klar M, Nusbaum DJ, *et al.* Utilization and outcomes of sentinel lymph node biopsy for early endometrial cancer. *Obstet Gynecol* 2022;139:809–20.
  - 17 Dioun S, Chen L, Melamed A, *et al.* Uptake and outcomes of sentinel lymph node mapping in women undergoing minimally invasive surgery for endometrial cancer. *BJOG* 2022;129:1591–9.
  - 18 Casarin J, Multinu F, Tortorella L, *et al.* Sentinel lymph node biopsy for robotic-assisted endometrial cancer staging: further improvement of perioperative outcomes. *Int J Gynecol Cancer* 2020;30:41–7.
  - 19 Carter J, Huang HQ, Armer J, *et al.* GOG 244 - the LymphEdema and Gynecologic cancer (LEG) study: the association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE). *Gynecol Oncol* 2019;155:452–60.
  - 20 Borčinová M, Ragosch V, Jarkovský J, *et al.* Challenges in lower limb lymphoedema assessment based on limb volume change: lessons learnt from the SENTIX prospective multicentre study. *Gynecol Oncol* 2022;164:76–84.
  - 21 Geppert B, Lönnerfors C, Bollino M, *et al.* Sentinel lymph node biopsy in endometrial cancer—feasibility, safety and lymphatic complications. *Gynecol Oncol* 2018;148:491–8.
  - 22 Moss HA, Havrilesky LJ. The use of patient-reported outcome tools in gynecologic oncology research, clinical practice, and value-based care. *Gynecol Oncol* 2018;148:12–8.
  - 23 Sisodia RC, Dewdney SB, Fader AN, *et al.* Patient reported outcomes measures in gynecologic oncology: a primer for clinical use, part I. *Gynecol Oncol* 2020;158:194–200.
  - 24 Karabuga H, Gultekin M, Tulunay G, *et al.* Assessing the quality of life in patients with endometrial cancer treated with adjuvant radiotherapy. *Int J Gynecol Cancer* 2015;25:1526–33.
  - 25 Yost KJ, Cheville AL, Al-Hilli MM, *et al.* Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life. *Obstet Gynecol* 2014;124(2 Pt 1):307–15.
  - 26 Abu-Rustum NR, Barakat RR. Observations on the role of circumflex iliac node resection and the etiology of lower extremity lymphedema following pelvic lymphadenectomy for gynecologic malignancy. *Gynecol Oncol* 2007;106:4–5.